Quantitative assessment of masking of neutralization epitopes in HIV-1

Vaccine

Volumn 29, Issue 39, 2011, Pages 6736-6741

  Agarwal, Alpna ^a   Hioe, Catarina E ^a,b   Swetnam, James ^a   Zolla Pazner, Susan ^a,b   Cardozo, Timothy ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Epitope; HIV 1; Masking; Neutralization; V3; Variable loop

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2219; MONOCLONAL ANTIBODY 2557; MONOCLONAL ANTIBODY 3074; MONOCLONAL ANTIBODY 447 52D; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANALYTICAL PARAMETERS; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; NEUTRALIZATION POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; EPITOPE MAPPING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY;

EID: 80051558293     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.052     Document Type: Article

References (17)

1. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004, 4(March (3)):199-210.
2. Burton D.R., Stanfield R.L., Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 2005, 102(October (42)):14943-14948.
3. Emini E.A., Schleif W.A., Nunberg J.H., Conley A.J., Eda Y., Tokiyoshi S., et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992, 355(February (6362)):728-730.
4. Andrus L., Prince A.M., Bernal I., McCormack P., Lee D.H., Gorny M.K., et al. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J Infect Dis 1998, 177(April (4)):889-897.
5. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73(May (5)):4009-4018.
6. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420(December (6916)):678-682.
7. Krachmarov C.P., Honnen W.J., Kayman S.C., Gorny M.K., Zolla-Pazner S., Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol 2006, 80(July (14)):7127-7135.
8. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422(March (6929)):307-312.
9. Rong R., Li B., Lynch R.M., Haaland R.E., Murphy M.K., Mulenga J., et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 2009, 5(September (9)):e1000594.
10. Cardozo T., Swetnam J., Pinter A., Krachmarov C., Nadas A., Almond D., et al. Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. AIDS Res Hum Retroviruses 2009, 25(April (4)):441-450.
11. Hioe C.E., Wrin T., Seaman M.S., Yu X., Wood B., Self S., et al. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One 2010, 5(4):e10254.
12. Swetnam J., Shmelkov E., Zolla-Pazner S., Cardozo T. Comparative Magnitude of Cross-Strain Conservation of HIV Variable Loop Neutralization Epitopes. PLoS One 2010, 5(12):e15994.
13. Jiang X., Burke V., Totrov M., Williams C., Cardozo T., Gorny M.K., et al. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol 2010.
14. Schweighardt B., Liu Y., Huang W., Chappey C., Lie Y.S., Petropoulos C.J., et al. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acq Immun Def Synd 2007, 46(September (1)):1-11.
15. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79(August (16)):10108-10125.
16. Cardozo T., Kimura T., Philpott S., Weiser B., Burger H., Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007, 23(March (3)):415-426.
17. Burke V., Williams C., Sukumaran M., Kim S.S., Li H., Wang X.H., et al. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure 2009, 17(November (11)):1538-1546.